GALT vs HUBS · $142.4M cap vs P/E 96, rev $1.79B
Galectin Therapeutics Inc (GALT) versus HubSpot Inc (HUBS) — a side-by-side from cached financials, not a winner call.
Galectin Therapeutics Inc (GALT) is a biotechnology company listed on US.
HubSpot Inc (HUBS) is a software - application company listed on NYSE.
GALT does not have a complete income-statement cache yet.
Latest reported HUBS revenue for 2026-06-30 was $1.79B. Net income was $75.9M. HUBS currently screens at market cap $9.36B and trailing P/E 96.2.
GALT currently screens at market cap $142.4M. HUBS currently screens at market cap $9.36B and trailing P/E 96.2.
Not investment advice. Open the GALT and HUBS stock pages for the full models.
Not investment advice.